Oruka Therapeutics, Inc. short interest in 2024
In 2024, Oruka Therapeutics, Inc.'s disclosed short interest ran from 1.35% of shares outstanding on 12 Jan 2024 to 4.13% on 31 Dec 2024, a change of +2.78 percentage points. The year's high was 36.57% on 30 Aug 2024 and its low 1.26% on 29 Feb 2024, averaging 16.89% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 108.87 days on 15 Aug 2024. Full history: Oruka Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 1.35% (12 Jan 2024)
- End of year
- 4.13% (31 Dec 2024)
- Change
- +2.78 pp
- High
- 36.57% (30 Aug 2024)
- Low
- 1.26% (29 Feb 2024)
- Average
- 16.89%
- Highest days to cover
- 108.87 (15 Aug 2024)
- SEC filings marked
- 8
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 1.35% | 7.12 | |
| 31 Jan 2024 | 1.30% | 6.58 | |
| 15 Feb 2024 | 1.28% | 7.09 | 10-K filed, results (8-K) |
| 29 Feb 2024 | 1.26% | 9.10 | |
| 15 Mar 2024 | 1.27% | 6.65 | |
| 28 Mar 2024 | 1.35% | 7.07 | |
| 30 Apr 2024 | 28.29% | 16.66 | 10-Q filed, results (8-K) |
| 15 May 2024 | 28.24% | 49.91 | |
| 31 May 2024 | 28.55% | 42.94 | |
| 14 Jun 2024 | 28.54% | 53.76 | |
| 28 Jun 2024 | 28.78% | 75.16 | |
| 15 Jul 2024 | 29.13% | 30.45 | |
| 31 Jul 2024 | 30.30% | 48.85 | |
| 15 Aug 2024 | 34.37% | 108.87 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 36.57% | 11.06 | |
| 13 Dec 2024 | 2.42% | 4.25 | results (8-K), 10-Q filed |
| 31 Dec 2024 | 4.13% | 2.66 |
See also: Oruka Therapeutics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.